Prognostic Biomarkers in Colorectal Cancer Outcomes and Mechanisms

Prognostic biomarkers in colorectal cancer encompass a diverse array of molecular, cellular and systemic indicators that predict patient outcomes, guide therapeutic decisions and illuminate underlying disease mechanisms. Classic tumour markers such as carcinoembryonic antigen (CEA), cancer antigens CA19-9 and CA125, and emerging inflammatory ratios reflect both tumour burden and host response. Advances in genetic and transcriptomic profiling have revealed mechanistic drivers of metastasis, including regulators of epithelial–mesenchymal transition and circulating tumour cell dissemination. Dynamic measurement strategies—incorporating longitudinal sampling and machine-learning algorithms—enhance risk stratification by capturing temporal fluctuations in biomarker levels. Integrating biomarker panels with clinical variables enables personalised survival modelling, improving prognostic accuracy beyond single-marker approaches. Globally, these developments hold promise for refining adjuvant therapy selection, monitoring minimal residual disease and identifying novel therapeutic targets. A mechanistic understanding of why certain markers correlate with relapse or survival fosters the translation of biomarker research into clinical practice, ultimately aiming to reduce mortality and optimise quality of life for patients with colorectal cancer.

Research from Nature Portfolio

Combined analyses of serum CEA, CA72-4, CA19-9, CA125 and ferritin in a large cohort have defined optimal marker panels for both diagnosis and prognostication. The study demonstrated that multi-marker combinations outperform single analytes in sensitivity and specificity, while positive preoperative levels of individual markers correlate with lymph node invasion, vascular and perineural involvement, and advanced pathological stage. These findings support the clinical utility of integrated serum assays to appraise tumour status and guide treatment planning.

Prognostic Biomarkers in Colorectal Cancer Outcomes and Mechanisms publication trend

The graph below shows the total number of articles in prognostic biomarkers in colorectal cancer outcomes and mechanisms across all publications each year (not limited to Nature Index journals).

Technical terms

Carcinoembryonic antigen (CEA): A glycoprotein commonly elevated in colorectal cancer, used to monitor treatment response and detect recurrence.

Cancer antigen 19-9 (CA19-9): A tumour-associated carbohydrate antigen whose serum concentration reflects tumour burden and may correlate with prognosis.

Neutrophil-to-lymphocyte ratio (NLR): An inflammation-based index calculated from routine blood counts, acting as a surrogate for systemic immune status and disease aggressiveness.

Epithelial–mesenchymal transition (EMT): A biological process in which epithelial cells acquire mesenchymal traits, increasing motility and contributing to metastatic spread.

Longitudinal measurement: Repeated assessments of biomarkers over time, enabling dynamic risk modelling and real-time prognostic updates.

References

1. Prediction models of colorectal cancer prognosis incorporating perioperative longitudinal serum tumor markers: a retrospective longitudinal cohort study. BMC Medicine (2023).
2. NCK-associated protein 1 regulates metastasis and is a novel prognostic marker for colorectal cancer. Cell Death Discovery (2023).
3. The prognostic utility of preoperative neutrophil-to-lymphocyte ratio (NLR) in patients with colorectal liver metastasis: a systematic review and meta-analysis. Cancer Cell International (2023).
4. Evaluation of Serum CEA, CA19-9, CA72-4, CA125 and Ferritin as Diagnostic Markers and Factors of Clinical Parameters for Colorectal Cancer. Scientific Reports (2018).